Engineered donor stem cell transplant for childhood blood cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new way to prepare donor stem cells before a transplant for children and young adults with blood cancers. The goal is to make the transplant safer and more effective, potentially reducing complications like graft-versus-host disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be younger than 22 years old and have a blood cancer that is in remission (no visible signs of disease) or in a state of incomplete recovery.
- You must be planning to receive a donor stem cell transplant with a strong conditioning regimen (high-dose chemotherapy or radiation).
- You must have a suitable donor: a fully matched sibling or unrelated donor, or a half-matched family member (haploidentical). Your doctor will check for donor availability.
- Your vital organs (heart, lungs, kidneys, liver) must be working well enough to tolerate the transplant. We'll run tests to check this.
- You must not have had a previous myeloablative transplant, be taking certain immune-suppressing medications, or have certain infections or other medical conditions that could make the transplant risky.
- You must be willing to avoid pregnancy or fathering a child for at least one year after the transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for people with advanced blood cancers who are getting a donor stem cell transplant. It aims to improve outcomes by using your own regulatory T cells along with the donor cells.
This Phase 1 trial studies Orca-Q to see if it is safe and works when added around the time of an allogeneic (donor) stem cell transplant for certain blood cancers. If you qualify, the study may offer a new option for managing the transplant immune response.
This trial tests a new cell therapy, orca-t, given after a lower-intensity chemo and radiation regimen for people with acute myeloid leukemia, mixed phenotype leukemia, or myelodysplastic syndrome. It aims to help patients who cannot tolerate full-intensity transplant conditioning.
This study looks at using stem cells from a donor's bone marrow or blood to treat blood cancers like leukemia or lymphoma. It compares transplants from partially matched donors with fully matched donors to see how well they work.
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.